Universal cancer therapies
Pro Research Analysisby 
Searched over 200M research papers
Universal Cancer Therapies: Current Strategies and Innovations
Universal CAR T Cell Therapy and Immune Receptors
Universal chimeric antigen receptor (CAR) T cell therapies are being developed to overcome the limitations of traditional CAR T cells, which target only a single tumor-associated antigen (TAA) and are often patient-specific. Universal immune receptors (UIRs) allow T cells to target multiple TAAs by using adapter molecules, enabling more flexible and controlled targeting of cancer cells. This approach can help address tumor heterogeneity and reduce the risk of antigen escape, while also allowing for dose control and improved safety compared to standard CAR T therapies Minutolo2019Urbańska2012. Universal CAR T cells can also be engineered to simultaneously attack both cancer cells and supportive cells in the tumor microenvironment, such as cancer-associated fibroblasts, enhancing tumor regression and immune cell infiltration without significant toxicity .
Off-the-Shelf and Allogeneic Universal T Cell Therapies
Traditional CAR T cell therapies are personalized, using a patient’s own cells, which can be costly and time-consuming. Universal, off-the-shelf CAR T therapies use cells from healthy donors, making treatment more accessible and scalable. However, challenges such as graft-versus-host disease (GVHD) and host rejection must be addressed. Strategies to overcome these issues include using T cells with unique natural features, such as virus-specific T cells, CD1- and MR1-restricted T cells, and γδ-TCR T cells, which are less likely to cause immune complications and can be broadly applied across patients Pérez2020Wang2023Zhang2020+1 MORE. Improving the expansion and persistence of these universal immune cells remains a key focus for enhancing their effectiveness .
Universal Cancer Vaccines and mRNA Therapies
Universal cancer vaccines aim to activate the immune system against a wide range of tumors, regardless of individual tumor mutations. Recent approaches use viral vectors or mRNA to engineer tumor cells to express highly immunogenic antigens, such as those from common pathogens (e.g., SARS-CoV-2 or hepatitis B virus). These strategies leverage pre-existing immunity in the population, allowing for rapid and robust anti-tumor responses and overcoming the challenges of tumor heterogeneity and slow immune activation seen with traditional vaccines Wu2025Fu2025. mRNA-based universal vaccines have shown the ability to reshape the tumor microenvironment and induce strong cytotoxic T cell responses in preclinical models .
Universal Therapeutic Targets and Combination Strategies
Researchers are also identifying universal therapeutic targets, such as the neurotrophic receptor tyrosine kinase (NTRK) gene fusion, which is present in many cancer types. Targeting such common drivers can make therapies applicable across a broad spectrum of tumors. Additionally, combining universal immunotherapies with other biological treatments, such as oncolytic viruses or cancer vaccines, is being explored to improve efficacy and overcome resistance mechanisms in the tumor microenvironment .
Conclusion
Universal cancer therapies are rapidly advancing, with promising strategies including universal CAR T cells, off-the-shelf allogeneic T cell products, and vaccines that harness pre-existing immunity. These approaches aim to make cancer treatment more accessible, effective, and broadly applicable, while addressing challenges such as tumor heterogeneity, immune escape, and treatment resistance. Continued innovation and clinical translation are expected to expand the reach and impact of universal cancer therapies in the near future Minutolo2019Pérez2020Wang2023+7 MORE.
Sources and full results
Most relevant research papers on this topic